Dive into our interview with co-founder of , to discover the driving force behind their groundbreaking tech. We are proud to support them at ViVe in Los Angeles and eagerly anticipate the exciting journey that lies ahead.
What motivated you and your co-founders to start Archangel AI?
The main event that motivated us to start Arkangel AI was my grandfather's misdiagnosis of cancer around 4 years ago. They made a mistake in the data analysis and were diagnosed too late. We found that the healthcare industry lacked the ability to read data and detect early diseases.
What are some challenges you are facing while scaling your start-up?
Right now, one of our main roadblocks is building a strong team and setting up a structure for the company to grow independently. Another challenge has been connecting with more potential customers; the international tour is a great opportunity for us because it allows us to create new opportunities and partners, expanding our network and connections.
How did the Dobson Centre play a role in Archangel as we know it today?
We started the company as an experiment but then saw an increase in users on the platform, and the Dobson Centre helped us structure and build our startup into what it is today. We first did a year of exploratory and business development and then landed our first big customers: AstraZeneca, Novartis, and Boston Scientific. The Dobson Centre has ultimately helped find new customers and expanded to different markets.
Who would be an ideal partner or collaborator for Archangel AI?
Some of our biggest goals would be to partner with Johnson and Johnson, GSK, or Bristol-Myers Squibb. We want to expand to new markets and meet with the innovation team across all departments associated with any disease.
What are you most excited about for ViVe in Los Angeles?
ViVe is the largest and most important conference in tech, so we are very excited to expand our network, and we already have a campaign to connect with potential partners. We also would like to assess synergies and challenges in the US market.
About Arkangel AI
is an AI as a service platform. We transform medical data from healthcare institutions to create AI algorithms automatically for early disease detection at scale. Any healthcare company like pharma, hospitals, or healthcare insurer gets a license to use our technology based on their use cases. Allowing physicians, researchers, and digital health developers to access to create their own AI models without code, to make decisions in real-time, optimize access, improve early detection patients' care worldwide and at a fraction of the cost. Arkangel AI has been developed with scientific entities such as Google, Novartis, and 不良研究所 Canada.
